Cargando…
Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant skin adnexal tumor. Recurrences are most often localized, and long-term follow-up after complete surgery consists essentially of self-examination of skin. We report one case of metastatic PCMC with elevated levels of serum CEA and CA15....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841795/ https://www.ncbi.nlm.nih.gov/pubmed/36655184 http://dx.doi.org/10.1159/000525524 |
_version_ | 1784869972576567296 |
---|---|
author | Ginguay, Antonin Kramkimel, Nora Lecolant, Solène Goldwasser, François Battistella, Maxime Arrondeau, Jennifer |
author_facet | Ginguay, Antonin Kramkimel, Nora Lecolant, Solène Goldwasser, François Battistella, Maxime Arrondeau, Jennifer |
author_sort | Ginguay, Antonin |
collection | PubMed |
description | Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant skin adnexal tumor. Recurrences are most often localized, and long-term follow-up after complete surgery consists essentially of self-examination of skin. We report one case of metastatic PCMC with elevated levels of serum CEA and CA15.3. Because of the difficulty to differentiate PCMC and metastasis of mucinous breast cancer, the hypothesis of a metastasized breast cancer was ruled out. These tumor markers contributed to the monitoring of the metastatic disease. Since metastatic disease was diagnosed after several years of seeming complete remission, CEA and CA15.3 would likely have allowed the clinicians to detect the relapse earlier. Although the use of tumor biomarkers in PCMC is not rooted in clinical practice and not mentioned in guidelines, we suggest that CEA and CA15.3 could be of particular interest to monitor and detect early metastatic PCMC. |
format | Online Article Text |
id | pubmed-9841795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-98417952023-01-17 Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? Ginguay, Antonin Kramkimel, Nora Lecolant, Solène Goldwasser, François Battistella, Maxime Arrondeau, Jennifer Case Rep Oncol Case Report Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant skin adnexal tumor. Recurrences are most often localized, and long-term follow-up after complete surgery consists essentially of self-examination of skin. We report one case of metastatic PCMC with elevated levels of serum CEA and CA15.3. Because of the difficulty to differentiate PCMC and metastasis of mucinous breast cancer, the hypothesis of a metastasized breast cancer was ruled out. These tumor markers contributed to the monitoring of the metastatic disease. Since metastatic disease was diagnosed after several years of seeming complete remission, CEA and CA15.3 would likely have allowed the clinicians to detect the relapse earlier. Although the use of tumor biomarkers in PCMC is not rooted in clinical practice and not mentioned in guidelines, we suggest that CEA and CA15.3 could be of particular interest to monitor and detect early metastatic PCMC. S. Karger AG 2022-12-21 /pmc/articles/PMC9841795/ /pubmed/36655184 http://dx.doi.org/10.1159/000525524 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Ginguay, Antonin Kramkimel, Nora Lecolant, Solène Goldwasser, François Battistella, Maxime Arrondeau, Jennifer Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? |
title | Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? |
title_full | Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? |
title_fullStr | Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? |
title_full_unstemmed | Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? |
title_short | Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? |
title_sort | primary cutaneous mucinous carcinoma monitoring: a role for ca15.3 and cea? |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841795/ https://www.ncbi.nlm.nih.gov/pubmed/36655184 http://dx.doi.org/10.1159/000525524 |
work_keys_str_mv | AT ginguayantonin primarycutaneousmucinouscarcinomamonitoringaroleforca153andcea AT kramkimelnora primarycutaneousmucinouscarcinomamonitoringaroleforca153andcea AT lecolantsolene primarycutaneousmucinouscarcinomamonitoringaroleforca153andcea AT goldwasserfrancois primarycutaneousmucinouscarcinomamonitoringaroleforca153andcea AT battistellamaxime primarycutaneousmucinouscarcinomamonitoringaroleforca153andcea AT arrondeaujennifer primarycutaneousmucinouscarcinomamonitoringaroleforca153andcea |